Trial reportMedicine2025
Therapeutic efficacy of quetiapine combined with magnesium valproate in schizophrenia: Impact on serum BDNF and GFAP levels.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neurotrophin System as a Complex Set of Potential Biomarkers in Psychiatric Disorders and Therapy-Overview of Recent Advances.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the clinical efficacy and biomarker effects of quetiapine combined with magnesium valproate in patients with schizophrenia. A total of 156 patients diagnosed with schizophrenia were randomly assigned to 2 groups: 1 received magnesium valproate monotherapy (n = 78), and the other received combined therapy with quetiapine and magnesium valproate (n = 78). Both groups were treated for 8 weeks. Serum brain-derived neurotrophic factor and GFAP concentrations were measured before and after treatment. Clinical efficacy was assessed using the positive and negative syndrome scale, Montreal Cognitive Assessment, and a schizophrenia-specific quality of life scale. Adverse events were monitored and compared. After 8 weeks of treatment, serum brain-derived neurotrophic factor concentrations increased significantly in the combination group (628.63 ± 154.09 pg/mL) compared with the monotherapy group (520.78 ± 133.44 pg/mL, P < .001). Meanwhile, GFAP concentrations decreased to 2.16 ± 0.23 μg/L in the combination group versus 2.36 ± 0.30 μg/L in the monotherapy group (P < .001). Positive and negative syndrome scale total scores decreased more substantially in the combination group (101.41 ± 11.36 to 74.54 ± 8.41) than in the monotherapy group (101.33 ± 9.85 to 89.22 ± 9.06, P < .001). Montreal Cognitive Assessment scores improved to 26.15 ± 3.36 in the combination group compared with 22.24 ± 3.64 in the monotherapy group (P < .001). Quality of life scores also improved more in the combination group (total: 73.41 ± 5.49) than in the monotherapy group (82.92 ± 5.57, P < .001; lower scores indicate better quality of life). The incidence of adverse reactions was comparable between groups, occurring in 8 of 78 patients (10.26%) in the combination group and 7 of 78 patients (8.97%) in the monotherapy group (χ²=0.074, P = .786). Quetiapine combined with magnesium valproate offers superior clinical benefits over monotherapy in patients with schizophrenia. It significantly improves psychiatric symptoms, cognitive function, and quality of life, likely through modulation of neurotrophic and glial activity, with good tolerability and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.